Investment Highlights
-RBCC has acquired a new equity interest in Nano3D Biosciences, Inc. (n3D). - yes, as stated earlier, 0.0081% with no promise of ever getting a payout, nor the cash flow to purchase the remaining equity interest (up to 5%) in n3D.
-n3D's nanoparticle technology could completely revolutionize cell research. - sure, maybe decades from now....
-RBCC is spearheading the most innovative scientific and medical breakthroughs in the $84.6 billion global biotech industry. - prove it - how?
-U.S. biotech companies raised $25 billion in 2010--a 15-percent jump over the previous year's investment total, according to Ernst & Young. - none of which is even relevant to RBCC.
-RBCC is joining the ranks of bioscience companies like Puma - a company that recently announced a private placement of 14.7 million shares of its common stock to investors, resulting in proceeds of $55 million. - huh? how? with no bio-science assets, no cash, and no employees with relevant experience, please do explain?!
You forgot to include a reference to the 52 week high of $34.60 and the freefall to currect level of about $0.40!!
